Skip to main content
OpenTrials
Completed

NCT Number: NCT04676256

Early VItrectomy in DENse Spontaneous Vitreous HEmorrhage

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Lariboisiere

Paris, Île-de-France Region, 75010, France

About this study

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Scientific background Spontaneous vitreous hemorrhage may occur after spontaneous posterior vitreous detachment and causes retinal break and retinal detachment in about 70% and 40% of cases respectively. The fundus examination and ultrasound have limited sensitivity to detect retinal breaks in these cases. Some retrospective studies have highlighted the benefit of an early vitrectomy for decreasing the rate of visual loss due to retinal detachment in these cases. However, to date, there is no national or international consensus regarding the management of spontaneous vitreous hemorrhage and the timing of vitrectomy.

Study design Prospective randomized clinical trial Primary objective To compare the results of an early vitrectomy versus ultrasound and fundus observation in spontaneous vitreous hemorrhage.

Secondary objectives To evaluate the rate of retinal complications in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

To evaluate the rate of visual loss in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

Primary criteria Rate of retinal detachment in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Secondary criteria Rate of retinal breaks and vitreo-retinal proliferation in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Visual acuity and rate of eyes with a loss of 5 letters or more among eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Participants Patients with a spontaneous vitreous hemorrhage secondary to posterior vitreous detachment, with a reduced visibility of the fundus Inclusion criteria

  • Age > or = 18 years old
  • Spontaneous vitreous hemorrhage which is 1/ secondary to posterior vitreous detachment; 2/ acute: which duration is < 15 days, 3/ dense: reduced visibility of the fundus

Exclusion criteria

  • Retinal detachment at the initial examination
  • Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
  • Any history of uveitis, age-related macular degeneration
  • History of a recent ocular traumatism (< 3 months)
  • History of a recent retinal laser treatment (< 3 months) or vitreo-retinal surgery (< 3 months)
  • Absence of consent Experimental group Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63) Active Comparator group Eyes with spontaneous vitreous hemorrhage only observed using fundus examination and B-ultrasound (n = 63) Study duration Inclusion: 12 months Participation: 6 months Total duration: 18 months

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > or = 18 years old
  • Spontaneous vitreous hemorrhage which is :
  • secondary to posterior vitreous detachment;
  • acute: which duration is < 15 days,
  • dense: reduced visibility of the fundus

Exclusion criteria

  • Retinal detachment at the initial examination
  • Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
  • Any history of uveitis, age-related macular degeneration
  • History of a recent ocular traumatism (< 3 months)
  • History of a recent retinal laser treatment (< 3 months) or vitreo-retinal surgery (< 3 months)
  • Absence of oral and written consent

Treatment and study plan

Early vitrectomy

Procedure

Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

Primary outcomes

  1. Rate of retinal detachment

    Time frame: 6 months after intervention

    number of eyes with a retinal detachment in each group. The presence of retinal detachment will be assessed on fundus examination

Secondary outcomes

  1. Rate of retinal breaks

    Time frame: 6 months after intervention

    number of eyes with a retinal breaks in each group. The presence of retinal breaks will be assessed on fundus examination

  2. Rate vitreo-retinal proliferation

    Time frame: 6 months after intervention

    number of eyes with a vitreo-retinal proliferation in each group. The presence of vitreo-retinal proliferation will be assessed on fundus examination

  3. Visual acuity

    Time frame: 6 months after intervention

    visual acuity will be measured using Snellen and/or ETDRS chart

  4. Rate of eyes with a loss of 5 letters or more

    Time frame: 6 months after intervention

  5. Rate of cataract

    Time frame: 6 months after intervention

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Comparaison de la Vitrectomie précoce et de la Surveillance Simple Dans la Prise en Charge Des hémorragies du vitré spontanées EVIDENSE Early VItrectomy in DENse Spontaneous Vitreous HEmorrhage

Acronym: EVIDENSE

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Dec 21, 2020
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.